These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38580648)

  • 1. Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors.
    Fried W; Tyagi M; Minakhin L; Chandramouly G; Tredinnick T; Ramanjulu M; Auerbacher W; Calbert M; Rusanov T; Hoang T; Borisonnik N; Betsch R; Krais JJ; Wang Y; Vekariya UM; Gordon J; Morton G; Kent T; Skorski T; Johnson N; Childers W; Chen XS; Pomerantz RT
    Nat Commun; 2024 Apr; 15(1):2862. PubMed ID: 38580648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
    Zatreanu D; Robinson HMR; Alkhatib O; Boursier M; Finch H; Geo L; Grande D; Grinkevich V; Heald RA; Langdon S; Majithiya J; McWhirter C; Martin NMB; Moore S; Neves J; Rajendra E; Ranzani M; Schaedler T; Stockley M; Wiggins K; Brough R; Sridhar S; Gulati A; Shao N; Badder LM; Novo D; Knight EG; Marlow R; Haider S; Callen E; Hewitt G; Schimmel J; Prevo R; Alli C; Ferdinand A; Bell C; Blencowe P; Bot C; Calder M; Charles M; Curry J; Ekwuru T; Ewings K; Krajewski W; MacDonald E; McCarron H; Pang L; Pedder C; Rigoreau L; Swarbrick M; Wheatley E; Willis S; Wong AC; Nussenzweig A; Tijsterman M; Tutt A; Boulton SJ; Higgins GS; Pettitt SJ; Smith GCM; Lord CJ
    Nat Commun; 2021 Jun; 12(1):3636. PubMed ID: 34140467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination-Deficient Leukemia Cells.
    Sullivan-Reed K; Toma MM; Drzewiecka M; Nieborowska-Skorska M; Nejati R; Karami A; Wasik MA; Sliwinski T; Skorski T
    Mol Cancer Res; 2023 Oct; 21(10):1017-1022. PubMed ID: 37358557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for a Polθ helicase small-molecule inhibitor revealed by cryo-EM.
    Ito F; Li Z; Minakhin L; Chandramouly G; Tyagi M; Betsch R; Krais JJ; Taberi B; Vekariya U; Calbert M; Skorski T; Johnson N; Chen XS; Pomerantz RT
    Nat Commun; 2024 Aug; 15(1):7003. PubMed ID: 39143110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic separation of Brca1 functions reveal mutation-dependent Polθ vulnerabilities.
    Krais JJ; Glass DJ; Chudoba I; Wang Y; Feng W; Simpson D; Patel P; Liu Z; Neumann-Domer R; Betsch RG; Bernhardy AJ; Bradbury AM; Conger J; Yueh WT; Nacson J; Pomerantz RT; Gupta GP; Testa JR; Johnson N
    Nat Commun; 2023 Nov; 14(1):7714. PubMed ID: 38001070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.
    Zhou J; Gelot C; Pantelidou C; Li A; Yücel H; Davis RE; Färkkilä A; Kochupurakkal B; Syed A; Shapiro GI; Tainer JA; Blagg BSJ; Ceccaldi R; D'Andrea AD
    Nat Cancer; 2021 Jun; 2(6):598-610. PubMed ID: 34179826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARPi, BRCA, and gaps: controversies and future research.
    Dibitetto D; Widmer CA; Rottenberg S
    Trends Cancer; 2024 Sep; 10(9):857-869. PubMed ID: 39004561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of synthetic lethality between BRCA1/2 and 53BP1 deficiencies and DNA polymerase theta targeting.
    Ronson GE; Starowicz K; Anthony EJ; Piberger AL; Clarke LC; Garvin AJ; Beggs AD; Whalley CM; Edmonds MJ; Beesley JFJ; Morris JR
    Nat Commun; 2023 Nov; 14(1):7834. PubMed ID: 38030626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors.
    Ma L; Chen W; Yang M; Ha S; Xiong S; Zhu J; Xiang H; Luo G
    J Med Chem; 2024 Mar; 67(5):3606-3625. PubMed ID: 38375763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.
    Ceccaldi R; Liu JC; Amunugama R; Hajdu I; Primack B; Petalcorin MI; O'Connor KW; Konstantinopoulos PA; Elledge SJ; Boulton SJ; Yusufzai T; D'Andrea AD
    Nature; 2015 Feb; 518(7538):258-62. PubMed ID: 25642963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small Molecules Targeting DNA Polymerase Theta (POLθ) as Promising Synthetic Lethal Agents for Precision Cancer Therapy.
    Pismataro MC; Astolfi A; Barreca ML; Pacetti M; Schenone S; Bandiera T; Carbone A; Massari S
    J Med Chem; 2023 May; 66(10):6498-6522. PubMed ID: 37134182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells.
    Verma P; Zhou Y; Cao Z; Deraska PV; Deb M; Arai E; Li W; Shao Y; Puentes L; Li Y; Patankar S; Mach RH; Faryabi RB; Shi J; Greenberg RA
    Nat Cell Biol; 2021 Feb; 23(2):160-171. PubMed ID: 33462394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
    Cong K; Peng M; Kousholt AN; Lee WTC; Lee S; Nayak S; Krais J; VanderVere-Carozza PS; Pawelczak KS; Calvo J; Panzarino NJ; Turchi JJ; Johnson N; Jonkers J; Rothenberg E; Cantor SB
    Mol Cell; 2021 Aug; 81(15):3128-3144.e7. PubMed ID: 34216544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polθ Inhibitor (ART558) Demonstrates a Synthetic Lethal Effect with PARP and RAD52 Inhibitors in Glioblastoma Cells.
    Barszczewska-Pietraszek G; Czarny P; Drzewiecka M; Błaszczyk M; Radek M; Synowiec E; Wigner-Jeziorska P; Sitarek P; Szemraj J; Skorski T; Śliwiński T
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51.
    Tao L; Zhou Y; Pan X; Luo Y; Qiu J; Zhou X; Chen Z; Li Y; Xu L; Zhou Y; Zuo Z; Liu C; Wang L; Liu X; Tian X; Su N; Yang Z; Zhang Y; Gou K; Sang N; Liu H; Zou J; Xiao Y; Zhong X; Xu J; Yang X; Xiao K; Liu Y; Yang S; Peng Y; Han J; Cen X; Zhao Y
    Nat Commun; 2023 Nov; 14(1):7430. PubMed ID: 37973845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.